These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 7800165)

  • 21. Dexamethasone suppression test: use of two different dexamethasone doses.
    Hwang S; Zander J; Garvey M
    J Clin Psychiatry; 1984 Sep; 45(9):390-2. PubMed ID: 6469924
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Negative and depressive symptoms in suicidal schizophrenics.
    Jones JS; Stein DJ; Stanley B; Guido JR; Winchel R; Stanley M
    Acta Psychiatr Scand; 1994 Feb; 89(2):81-7. PubMed ID: 8178667
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DST and schizophrenic symptomatology.
    Keshavan MS; Brar J; Ganguli R; Jarrett D
    Biol Psychiatry; 1989 Dec; 26(8):856-8. PubMed ID: 2590699
    [No Abstract]   [Full Text] [Related]  

  • 24. [Melatonin and schizophrenia].
    Fanget F; Claustrat B; Dalery J; Brun J; Terra JL; Marie-Cardine M; Guyotat J
    Encephale; 1989; 15(6):505-10. PubMed ID: 2575517
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dexamethasone nonsuppression in chronic schizophrenia.
    Whiteford HA; Riney SJ; Savala RA; Csernansky JG
    Acta Psychiatr Scand; 1988 Jan; 77(1):58-62. PubMed ID: 3273153
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The dexamethasone suppression test and residual schizophrenia.
    Harris VJ
    Am J Psychiatry; 1985 May; 142(5):659-60. PubMed ID: 3985211
    [No Abstract]   [Full Text] [Related]  

  • 27. The dexamethasone suppression test in schizophrenia.
    Sawyer J; Jeffries JJ
    J Clin Psychiatry; 1984 Sep; 45(9):399-402. PubMed ID: 6469927
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dexamethasone suppression test in schizophrenia: its relation to monoamine metabolism in hypothalamic-pituitary-adrenal axis.
    Kaneko M; Murata S; Hoshino Y; Takahagi K; Yokoyama F; Watanabe M; Kumashiro H
    Neuropsychobiology; 1990-1991; 24(1):12-6. PubMed ID: 2132636
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Platelet 5-HT and plasma cortisol concentrations after dexamethasone suppression test in patients with different time course of schizophrenia.
    Jakovljević M; Mück-Seler D; Pivac N; Crncević Z
    Neuropsychobiology; 1998; 37(3):142-5. PubMed ID: 9597670
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The incidence of abnormal dexamethasone suppression in schizophrenia: a review and a meta-analytic comparison with the incidence in normal controls.
    Yeragani VK
    Can J Psychiatry; 1990 Mar; 35(2):128-32. PubMed ID: 2138504
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cortisol and cytokines in chronic and treatment-resistant patients with schizophrenia: association with psychopathology and response to antipsychotics.
    Zhang XY; Zhou DF; Cao LY; Wu GY; Shen YC
    Neuropsychopharmacology; 2005 Aug; 30(8):1532-8. PubMed ID: 15886721
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Positive and negative symptoms in schizophrenia and the Dexamethasone Suppression Test.
    Tandon R; Silk KR; Greden JF; Goodson J; Hariharan M; Meador-Woodruff JH; Kronfol Z
    Biol Psychiatry; 1989 Mar; 25(6):788-92. PubMed ID: 2629711
    [No Abstract]   [Full Text] [Related]  

  • 33. Symptomatology and cognitive impairment associate independently with post-dexamethasone cortisol concentrations in unmedicated schizophrenic patients.
    Newcomer JW; Faustman WO; Whiteford HA; Moses JA; Csernansky JG
    Biol Psychiatry; 1991 May; 29(9):855-64. PubMed ID: 2049484
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The DST and outcome in schizophrenia.
    Tandon R; Mazzara C; Dequardo JR
    Am J Psychiatry; 1989 Dec; 146(12):1648-9. PubMed ID: 2589574
    [No Abstract]   [Full Text] [Related]  

  • 35. Seasonal variation in postdexamethasone cortisol values in depressed inpatients. Results of least squares cosine spectral analysis.
    Maes M; Schotte C
    J Affect Disord; 1997 Jun; 44(1):5-12. PubMed ID: 9186797
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dexamethasone suppression test in patients with primary obsessive-compulsive disorder and in healthy controls.
    Catapano F; Monteleone P; Maj M; Kemali D
    Neuropsychobiology; 1990; 23(2):53-6. PubMed ID: 2077433
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dexamethasone suppression test and suicide attempts in schizophrenic patients.
    Płocka-Lewandowska M; Araszkiewicz A; Rybakowski JK
    Eur Psychiatry; 2001 Nov; 16(7):428-31. PubMed ID: 11728857
    [TBL] [Abstract][Full Text] [Related]  

  • 38. First-episode neuroleptic-free schizophrenics: concentrations of monoamines and their metabolites in plasma and their correlations with clinical responses to haloperidol treatment.
    Nagaoka S; Iwamoto N; Arai H
    Biol Psychiatry; 1997 Apr; 41(8):857-64. PubMed ID: 9099412
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuroendocrine differences among subtypes of schizophrenic disorder? An investigation with the dexamethasone suppression test.
    Banki CM; Arató M; Rihmer Z
    Neuropsychobiology; 1984; 11(3):174-7. PubMed ID: 6472604
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma dexamethasone concentrations and differential suppression response of cortisol and corticosterone in depressives and controls.
    Holsboer F; Haack D; Gerken A; Vecsei P
    Biol Psychiatry; 1984 Mar; 19(3):281-91. PubMed ID: 6722226
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.